Publication:
Study protocol for a randomised controlled double-blinded trial of the dose-dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in uganda

dc.contributor.authorAlice Chijioke Eziefulaen_US
dc.contributor.authorSarah G. Staedkeen_US
dc.contributor.authorShunmay Yeungen_US
dc.contributor.authorEmily Webben_US
dc.contributor.authorMoses Kamyaen_US
dc.contributor.authorNicholas J. Whiteen_US
dc.contributor.authorTeun Bousemaen_US
dc.contributor.authorChris Drakeleyen_US
dc.contributor.otherLondon School of Hygiene & Tropical Medicineen_US
dc.contributor.otherInfectious Diseases Research Collaborationen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherRadboud University Nijmegen Medical Centreen_US
dc.date.accessioned2018-10-19T05:26:42Z
dc.date.available2018-10-19T05:26:42Z
dc.date.issued2013-04-17en_US
dc.description.abstractObjectives: For the purpose of blocking transmission of Plasmodium falciparum malaria from humans to mosquitoes, a single dose of primaquine is recommended by theWHO as an addition to artemisinin combination therapy. Primaquine clears gametocytes but causes dose-dependent haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Evidence is needed to inform the optimal dosing of primaquine for malaria elimination programmes and for the purpose of interrupting the spread of artemisininresistant malaria. This study investigates the efficacy and safety of reducing doses of primaquine for clearance of gametocytes in participants with normal G6PD status. Methods and analysis: In this prospective, fourarmed randomised placebo-controlled double-blinded trial, children aged 1-10 years, weighing over 10 kg, with haemoglobin ≥8 g/dl and uncomplicated P falciparum malaria are treated with artemether lumefantrine and randomised to receive a dose of primaquine (0.1, 0.4 or 0.75 mg base/kg) or placebo on the third day of treatment. Participants are followed up for 28 days. Gametocytaemia is measured by quantitative nucleic acid sequence-based analysis on days 0, 2, 3, 7, 10 and 14 with a primary endpoint of the number of days to gametocyte clearance in each treatment arm and secondarily the area under the curve of gametocyte density over time. Analysis is for non-inferiority of efficacy compared to the reference dose, 0.75 mg base/kg. Safety is assessed by pair-wise comparisons of the arithmetic mean (±SD) change in haemoglobin concentration per treatment arm and analysed for superiority to placebo and incidence of adverse events. Ethics and dissemination Approval was obtained from the ethical committees of Makerere University School of Medicine, the Ugandan National Council of Science and Technology and the London School of Hygiene and Tropical Medicine. Results: These will be disseminated to inform malaria elimination policy, through peer-reviewed publication and academic presentations.en_US
dc.identifier.citationBMJ Open. Vol.3, No.3 (2013)en_US
dc.identifier.doi10.1136/bmjopen-2013-002759en_US
dc.identifier.issn20446055en_US
dc.identifier.other2-s2.0-84876140818en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/32385
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84876140818&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleStudy protocol for a randomised controlled double-blinded trial of the dose-dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in ugandaen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84876140818&origin=inwarden_US

Files

Collections